NephroPlus to Open IPO on December 10; Price Band Set at ₹438–₹460

NephroPlus, Asia’s largest dialysis services provider and the world’s fifth-largest based on treatment volumes in Fiscal 2025, will launch its Initial Public Offering (IPO) on December 10, with subscriptions closing on December 12. The company has fixed a price band of ₹438–₹460 per share, including a ₹41 discount for eligible employees.

The IPO will comprise a fresh issue worth ₹353.4 crore and an offer for sale (OFS) of up to 1,12,53,102 shares by existing shareholders.

NephroPlus plans to allocate ₹129.1 crore from the issue proceeds to expand its dialysis clinic network across India, while ₹136 crore will go toward pre-payment or scheduled repayment of borrowings.

Founded in 2009, the company is India’s largest organised dialysis network, operating across 288 cities in 21 states and 4 Union Territories. Globally, NephroPlus runs 519 clinics, including 51 centres across the Philippines, Uzbekistan and Nepal. Its 165-bedded centre in Tashkent is recognized as the largest dialysis clinic in the world.

NephroPlus delivers a comprehensive portfolio of services—home haemodialysis, hemodiafiltration, holiday dialysis, dialysis on call, and dialysis on wheels—ensuring patients have access to personalised and convenient treatment choices.

India’s dialysis service market, valued at USD 818 million in Fiscal 2024, is expected to nearly triple to USD 1,979 million by 2029, driven by rising kidney disease prevalence and demand for specialised care.